Do you offer nivolumab for metastatic HCC in the second line or if sorafenib is intolerable?

Using nivolumab in second line if the patient cannot tolerate sorafenib is appropriate; the regorefanib RESORCE trial had selected patients who tolerated sorafenib at a minimum dose of 400 mg daily for 20 of the 28 days prior to study entry.

The challenge is the child pugh C status of the patient. We...